Clinical trials: Phase 2
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Crohn's Disease
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently…
- Trial name
- NCT00055536
- Testing
- natalizumab
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
NSCLC (Advanced Non-small Cell Lung Cancer)
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
This is a Phase 1b/2 study. In Phase 1b, subjects will know the treatment they are receiving. Subjects will receive Erlotinib + U3-1287.
- Trial name
- NCT01211483
- Testing
- U3-1287, Erlotinib
- Where
- 52 sites in United States, Austria and 11 more
- Volunteers
- 222 people
- Sponsor
- Daiichi Sankyo
Parkinson Disease
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
This trial is a late phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety, and pharmacokinetics of KDT-3594 administered at escalating doses ranging from 0.25…
- Trial name
- NCT06722729
- Testing
- KDT-3594
- Where
- Japan
- Volunteers
- 178 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Axial Spondyloarthritis, Ankylosing Spondylitis
Vilamakitug in Spondyloarthritis Placebo-controlled Investigation for Efficacy
The goal of this clinical trial is to find out if the study drug will work as a new therapy for axSpA patients. This study is placebo-controlled, and evaluates if study drug can treat symptoms of axSpA, including global disease…
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, r-axSpA, Nr-axSpA
- Trial name
- V-SPINE (NCT06526377)
- Testing
- vilamakitug
- Volunteers
- 150 people
- Sponsor
- XBiotech, Inc.
Eczema Atopic Dermatitis, Eczema
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis…
- Conditions
- Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
- Trial name
- GX-03 in AD (NCT07355075)
- Testing
- GX-03, Vehicle
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- Turn Therapeutics
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Atrial Flutter
A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter
This study will attempt to demonstrate the effectiveness of RSD1235 in the conversion of atrial flutter (AFL) to sinus rhythm.
- Trial name
- Scene 2 (NCT00476112)
- Testing
- Vernakalant Injection 20 mg/mL
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Advanz Pharma
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral…
- Trial name
- NCT00437112
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and DPP-4 inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242228
- Testing
- ipragliflozin, DPP-4 inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Astellas Pharma Inc
Oral Mucositis
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
The purpose of the study is to evaluate the efficacy, safety and tolerability of topically administered AG013 compared to placebo for reducing Oral Mucositis (OM) in patients undergoing chemoradiation for the treatment of head…
- Trial name
- NCT03234465
- Testing
- AG013
- Where
- 50 sites in United States, Belgium and 2 more
- Volunteers
- 200 people
- Sponsor
- Oragenics, Inc.
Alcoholic Liver Cirrhosis
Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis
This study will evaluate the safety and efficacy of mesenchymal stem cells in patients with cirrhosis of liver. Stem cells will be injected into the hepatic artery. Improvement in various parameters will be observed over 2 years.
- Trial name
- NCT01591200
- Testing
- Allogeneic Mesenchymal Stem Cells
- Where
- 10 sites in India
- Volunteers
- 40 people
- Sponsor
- Stempeutics Research Pvt Ltd
Hepatitis B, Liver Transplantation
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection.
- Trial name
- NCT00228592
- Testing
- HepeX-B, Hepatitis B Immune Globulin (HBIg)
- Where
- 20 sites in United States, France and 5 more
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NASH - Nonalcoholic Steatohepatitis
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Trial name
- HM-TRIA-201 (NCT04505436)
- Testing
- HM15211
- Where
- 60 sites in United States, South Korea
- Volunteers
- 215 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Postsurgical Pain
Study of CA-008 (Vocacapsaicin) in Total Knee Arthroplasty
This is a two-part, Phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel design study of CA-008 (vocacapsaicin) vs. placebo injected/instilled during an elective TKA.
- Trial name
- NCT03731364
- Testing
- CA-008
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Concentric Analgesics
Non-Small Cell Lung Cancer
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.
- Trial name
- NCT07256509
- Testing
- SYS6010, Osimertinib, Pemetrexed
- Volunteers
- 120 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Spinal Muscular Atrophy Type I
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1.
- Trial name
- NCT07070999
- Testing
- GB221
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Gemma Biotherapeutics
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Type 2 Diabetes Mellitus
A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin
In this study the effect of ipragliflozin on glucose homeostasis in healthy subjects and T2DM subjects, and the effect of exposure of ipragliflozin on urinary glucose excretion and plasma glucose in T2DM subjects will be…
- Trial name
- NCT01611363
- Testing
- ASP1941
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.